Related Experiment Video
Updated: Jun 14, 2026
06:43
Increased Recovery Time and Decreased LPS Administration to Study the Vagus Nerve Stimulation Mechanisms in Limited Inflammatory Responses
Published on: March 29, 2017
Peripheral site acetylcholinesterase inhibitors targeting both inflammation and cholinergic dysfunction
Sherri Young1, Karine Fabio, Christophe Guillon
1Department of Chemistry, Lehigh University, Bethlehem, PA 18015, USA.
Bioorganic & Medicinal Chemistry Letters
|March 30, 2010
Summary
Researchers designed novel noncompetitive acetylcholinesterase inhibitors (AChEIs) that also act as NSAID prodrugs. These potent AChEIs offer dual therapeutic potential for inflammation by releasing NSAIDs and up-regulating the cholinergic anti-inflammatory pathway.
Area of Science:
- Medicinal Chemistry
- Neuroscience
- Pharmacology
Background:
- Acetylcholinesterase inhibitors (AChEIs) are crucial for treating neurodegenerative diseases.
- Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used to manage inflammation.
- Developing agents with dual therapeutic actions is a key goal in drug discovery.
Purpose of the Study:
- To design and investigate novel noncompetitive AChEIs that also function as NSAID prodrugs.
- To explore the potential of these dual-action agents in managing inflammatory conditions.
- To identify structural features correlating with potent acetylcholinesterase inhibition.
Main Methods:
- Synthesis of two distinct classes of noncompetitive AChEIs.
- Incorporation of NSAID moieties and lipophilic choline mimics.
- Structure-activity relationship studies focusing on linker design (aromatic alkyl-aryl).
- In vitro assessment of acetylcholinesterase (AChE) inhibition.
Main Results:
- Identified potent noncompetitive AChEIs with submicromolar inhibitory activity.
- The most effective compounds featured an aromatic alkyl-aryl linker connecting the NSAID and choline mimic.
- Demonstrated the prodrug potential for in vivo NSAID release.
- Indicated activation of the cholinergic anti-inflammatory pathway via cholinergic up-regulation.
Conclusions:
- Novel noncompetitive AChEIs with NSAID prodrug capabilities were successfully designed and studied.
- These agents hold therapeutic promise for simultaneously addressing inflammation and enhancing cholinergic signaling.
- The developed compounds represent a promising strategy for dual-target therapy in inflammatory diseases.
Related Concept Videos
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
00:59Direct-Acting Cholinergic Agonists: Pharmacological Actions
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
01:26Anticholinesterase Agents: Poisoning and Treatment
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...